Stockreport

Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Lyra Therapeutics, Inc.  (LYRA) 
PDF Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENL [Read more]